Barclays PLC Has $3.63 Million Stake in AtriCure, Inc. (NASDAQ:ATRC)

Barclays PLC lowered its stake in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 57.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 129,265 shares of the medical device company's stock after selling 174,803 shares during the quarter. Barclays PLC owned approximately 0.27% of AtriCure worth $3,625,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Arcadia Investment Management Corp MI acquired a new position in shares of AtriCure during the third quarter valued at $28,000. Quest Partners LLC boosted its stake in AtriCure by 38.3% during the 2nd quarter. Quest Partners LLC now owns 5,868 shares of the medical device company's stock valued at $134,000 after purchasing an additional 1,626 shares during the period. nVerses Capital LLC grew its position in AtriCure by 733.3% in the 3rd quarter. nVerses Capital LLC now owns 5,000 shares of the medical device company's stock worth $140,000 after purchasing an additional 4,400 shares during the last quarter. Mount Yale Investment Advisors LLC raised its holdings in shares of AtriCure by 32.1% during the second quarter. Mount Yale Investment Advisors LLC now owns 9,743 shares of the medical device company's stock valued at $222,000 after buying an additional 2,368 shares during the last quarter. Finally, Captrust Financial Advisors acquired a new position in shares of AtriCure during the third quarter worth approximately $230,000. 99.11% of the stock is currently owned by institutional investors.

AtriCure Price Performance

Shares of ATRC traded down $0.21 during mid-day trading on Monday, hitting $30.51. The company's stock had a trading volume of 333,746 shares, compared to its average volume of 693,870. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.62 and a quick ratio of 2.59. The firm has a 50-day moving average price of $33.35 and a 200 day moving average price of $27.60. AtriCure, Inc. has a fifty-two week low of $18.94 and a fifty-two week high of $39.04. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of -36.76 and a beta of 1.40.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The medical device company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.02. The business had revenue of $115.91 million during the quarter, compared to analyst estimates of $112.23 million. AtriCure had a negative return on equity of 8.12% and a negative net margin of 8.70%. The company's revenue was up 17.9% compared to the same quarter last year. During the same period last year, the company posted ($0.20) EPS. On average, research analysts predict that AtriCure, Inc. will post -0.72 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on ATRC shares. JPMorgan Chase & Co. reaffirmed an "overweight" rating and set a $40.00 target price on shares of AtriCure in a research note on Tuesday, December 17th. Canaccord Genuity Group lifted their price objective on shares of AtriCure from $53.00 to $61.00 and gave the company a "buy" rating in a research note on Monday, December 9th. Oppenheimer upped their price objective on shares of AtriCure from $32.00 to $36.00 and gave the stock an "outperform" rating in a report on Wednesday, October 30th. StockNews.com raised shares of AtriCure from a "sell" rating to a "hold" rating in a research note on Saturday, September 14th. Finally, UBS Group upped their price target on shares of AtriCure from $35.00 to $40.00 and gave the stock a "buy" rating in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $42.00.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.